About us

Tiziana Life Sciences is a NASDAQ listed (NASDAQ:TLSA) clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases . Our clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.

Mission

Our mission is to bring breakthrough therapies with the aim of treating SPMS, Crohn's Disease and KRAS+ NSCLC and optimizing health outcomes.

Vision

We are developing transformational formulation technologies, enabling to switch from traditional routes to alternative routes of immunotherapy to facilitate local site of action. For example, nasal, oral and inhalation administrations to target neurodegenerative and lung diseases. We believe, if we succeed in these alternative routes of immunotherapies that has the potential to change the way immunotherapies are currently conducted. 

Corporate Documents

View our latest investor presentation Investor Deck

Corporate Reorganisation

Tiziana has concluded its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group. The reorganisation was achieved by a scheme of arrangement under Part 26 of the Companies Act 2006.

Old Tiziana Articles

New Tiziana Bye Laws

(New Tiziana) Tiziana Life Sciences Ltd. Memorandum of Association

Old Share Option Scheme (2014)

Old Tiziana Old Share Option Scheme (2016)

Tiziana 2021 Equity Incentive Plan

Tiziana 2021 Equity Incentive Plan UK Supplement Addendum (Tiziana 2021 Equity Incentive Plan

Tiziana Life Sciences LTD Scheme Document